Background: In this study, the association of asthma with CD53, a member of the tetraspanin family, was assessed for the first time in a mechanism-based study.

Methods: Genetic polymorphisms of CD53 were analyzed in 591 subjects and confirmed in a replication study of 1001 subjects. CD53 mRNA and protein levels were measured in peripheral blood leukocytes, and the effects of the promoter polymorphisms on nuclear factor binding were examined by electrophoretic mobility shift assay. Cellular functional studies were conducted by siRNA transfections.

Results: Among tagging SNPs of CD53, the -1560 C>T in the promoter region was significantly associated with asthma risk. Compared with the CC genotype, the CT and TT genotypes were associated with a higher asthma risk, with odd ratios of 1.74 (P=0.009) and 2.03 (P=0.004), respectively. These findings were confirmed in the replication study with odd ratios of 1.355 (P=0.047) and 1.495 (P=0.039), respectively. The -1560 C>T promoter SNP had functional effects on nuclear protein binding as well as mRNA and protein expression levels in peripheral blood leukocytes. When CD53 was knocked down by siRNA in THP-1 human monocytic cells stimulated with house dust mite, the production of inflammatory cytokines as well as NFκB activity was significantly over-activated, suggesting that CD53 suppresses over-activation of inflammatory responses.

Conclusions: The -1560 C>T SNP is a functional promoter polymorphism that is significantly associated with population asthma risk, and is thought to act by directly modulating nuclear protein binding, thereby altering the expression of CD53, a suppressor of inflammatory cytokine production.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbagen.2012.12.030DOI Listing

Publication Analysis

Top Keywords

asthma risk
16
-1560 c>t
16
cd53
8
cd53 suppressor
8
suppressor inflammatory
8
inflammatory cytokine
8
cytokine production
8
associated population
8
population asthma
8
functional promoter
8

Similar Publications

The small airways comprise generations 8 to 23 of the bronchial tree, consist of airways with an internal diameter <2mm, and are classically difficult to assess and treat in persistent asthma. Small airways dysfunction (SAD) is integral to the asthma management paradigm as it is associated with poorer symptom control, greater levels of type 2 inflammation, and has been proposed as a potential treatable asthma trait. Although identification of SAD by oscillometry has been found to be clinically useful in managing asthma, very few physicians, including specialists, use this technique as part of standard or adjunct evaluation of lung function to diagnose asthma, grade severity of airway obstruction, ascertain disease control or the risk for future exacerbations or to make management decisions.

View Article and Find Full Text PDF

Background: Respiratory infections in early life is one identified risk factor for asthma. We hypothesized that infection preventive measures during the COVID-19 pandemic influenced the risk of respiratory morbidity and aeroallergen sensitization in early childhood.

Objective: To compare respiratory morbidity and aeroallergen sensitization in children born before and during the pandemic.

View Article and Find Full Text PDF

Management of eosinophilic otitis media in the era of biological therapy: systematic review and proportion meta-analysis.

Rhinology

December 2024

Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Background: Eosinophilic otitis media (EOM) is a recently recognised type 2 inflammatory disease, strongly associated with asthma and chronic rhinosinusitis with nasal polyps. Known as a difficult-to-treat condition, EOM is often refractory to traditional therapies for (chronic) otitis media. This review aims to assess the success rates of the different interventions for patients with EOM including newly available biological therapy.

View Article and Find Full Text PDF

Introduction: The article discusses topical issues of the use of conjugated 13-valent pneumococcal vaccine Prevenar®13 (PCV13) in patients with severe bronchial asthma (SBA), including those receiving targeted therapy with genetically engineered biological drugs (GEBD).

Aim: To study the effectiveness of vaccination against pneumococcal infection (PI) in patients with SBA.

Materials And Methods: The study included 381 patients with SBA.

View Article and Find Full Text PDF

Background: The increasing number of motor vehicles in Dhaka city is contributing to a rise in air pollution. Prolonged exposure to vehicle emissions has led to various health issues for everyone, but traffic policies might be particularly affected. This study aims to evaluate their knowledge, attitudes, and practices regarding air pollution, with the goal of raising awareness and promoting healthier practices to mitigate the adverse effects of pollution.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!